Impact of Visual Field Restriction on Visual Exploration (REVE)

Impact de la Restriction du Champ Visuel Sur l'Exploration Visuelle

To communicate with the observer and guide his gaze on the canvas, painters have developed different stylistic processes that artists, in the manner of scientists, have acquired on the functioning of human visual perception. This direct communication between the artist and the observer is strongly impacted for people with visual impairments.

In order to improve the accessibility and autonomy of visually impaired people in museums and to allow each observer to feel the visual and emotional experience closest to the original work of the artist, it is essential to identify the modifications. perceptive generated by the constriction of vision

Study Overview

• Status: Unknown
• Conditions: Pigmentary Retinopathy
• Intervention / Treatment: Other: Eye tracker

Detailed Description

In this experiment, the investigators study the adaptive strategies developed by people with retinitis pigmentosa in the perception of figurative works of art. Peripheral vision is crucial for detecting objects and directing attention to the relevant areas of the environment, while central vision, of high spatial resolution, is especially essential for identifying the nature of objects. The integration of perceived information in peripheral vision and central vision makes it possible to quickly and effortlessly develop a spatial representation of the environment, to activate categorical knowledge on the observed scene and to relate the various objects perceived. However, with the progressive constriction of the visual field, the visual exploration of the subject RP can not be carried out with the strategies used by the healthy subjects, in which the targets of the saccades are in particular determined according to the information perceived in peripheral vision.

Through the recording of eye movements, the investigators compare the differences in visual explorations of people with retinitis pigmentosa and healthy people with or without a simulated deficit.

• Study Type: Observational
• Enrollment (Anticipated): 45

Contacts and Locations

Study Locations

• France
  • Paris, France, 75012
    • Recruiting
    • Institut de la Vision
    • Contact: Avinoam Safran; Email: absafran@gmail.com
    • Contact: Alexis Defer; Phone Number: 0153462704; Email: alexis.defer@streetlab-vision.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Subjects with pigmentary retinopathy

Description

Groupe 1

Inclusion Criteria:

• no visual pathology
• Age ≥ 18 and <65 years
• Binocular visual acuity ≥8 / 10th or ≤ +0.10 logMAR
• Comprehension of the written and spoken French language
• Signed consent to participate in the study
• Health insurance affiliation
• Visit to an ophthalmologist less than a year old

Exclusion Criteria:

• Pregnant or lactating woman
• Ocular pathology that may interfere with planned assessments
• Treatment that may interfere with planned assessments
• Participation in another study that may interfere with this study.
• Severe pathology unbalanced or interfering with planned assessments.
• Neurological deficit including history of epileptic pathology, photosensitive epilepsy, sensory-motor coordination disorders, vestibular or cerebellar pathology
• Inability to give consent personally.
• Adults protected by law.

Groupe 2

Inclusion Criteria:

• Retinopathy pigmentary dystrophy rods-cones.
• Binocular visual acuity ≥4 / 10 (≤0.4 logMAR).
• Horizontal diameter of the residual Goldmann field of view ≤ 25 ° of binocular diameter at III4.
• Comprehension of the French language, written or oral.
• Signed consent
• Visual assessment less than 6 months old

Exclusion Criteria:

• Pregnant or nursing woman.
• Ocular pathology that may interfere with planned assessments.
• Treatment that may interfere with planned assessments.
• Severe pathology unbalanced or interfering with planned assessments.
• Participation in another study that may interfere with this study.
• Neurological deficit including antecedent of epileptic pathology, photosensitive epilepsies, non-visual sensory disturbances, motor disorders, or sensorimotor coordination disorders, vestibular or cerebellar pathology.
• Inability to give consent personally.
• Adults protected by law.

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Healthy volunteers	Other: Eye tracker; In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded
Retinopathy pigment; Patients with retinopathy pigment	Other: Eye tracker; In visual search tasks, participants will sit in front of a screen and observe during each visual scene for a maximum of 45 seconds. Their eye movements will be recorded

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Eye movements	Eye movements will be recorded by an eye trackervisual impairment whose peripheral visual field is masked They will be invited to observe scenes of human interaction presented on photographs, pictorial works or artificial scenes with or without prior instruction. In addition to the elementary variables recorded during the exploration by these subjects, such as the number, the amplitude or the orientation of the saccades, the sequence of fixations will be analyzed to define the exploratory strategy used.	through study completion,, an average of 1 year
Fixation strategy	The fixation strategy characterized by the path of the gaze of the subjects on the screen to locate the targets.	through study completion,, an average of 1 year
Target location accuracy	Target location accuracy, defined by the distance between the point of re-fixation on the target and the actual position of the target	through study completion,, an average of 1 year

Collaborators and Investigators

• Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
• Investigators: Principal Investigator: Avinoam Safran, Institut de la Vision

Study record dates

Study Major Dates

• Study Start (Actual): November 4, 2019
• Primary Completion (Anticipated): September 11, 2020
• Study Completion (Anticipated): October 17, 2021

Study Registration Dates

• First Submitted: October 23, 2019
• First Submitted That Met QC Criteria: April 21, 2020
• First Posted (Actual): April 24, 2020

Study Record Updates

• Last Update Posted (Actual): April 24, 2020
• Last Update Submitted That Met QC Criteria: April 21, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Genetic Diseases, Inborn; Eye Diseases, Hereditary; Retinal Dystrophies; Retinitis Pigmentosa
• Other Study ID Numbers: P19-05; 2019-A01198-49 (Other Identifier: N°IDRCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No